DOCSLIB.ORG

Euregio Laboratory Services MCP Aimed at Horses – Pharmacologic Drug Library

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Euregio Laboratory Services MCP Aimed at Horses – Pharmacologic Drug Library Euregio Laboratory Services MCP aimed at horses – pharmacologic drug library (preferably in urine) Acebutolol, Acemetacine, Acenocoumarol, Acepromazine, Acetanilide, Acetazolamide, Acetominophen (paracetamol), Adinazolam, Adiphenine, Albuterol (Salbutamol), Alfentanil, Allopurinol, Almotriptan, Alprazolam, Alprenolol, Amantadine, Ambroxol, Ambucetamide, Amfepramone, Amfetaminil, Amiloride, Amineptine, Aminoglutethimide, Aminorex, Amiodaron, Amiphenazol, Amisulpride, Amitriptylline, Amlodipine, Amobarbital, Amodiaquine, Amoxapine, Amperozide, Amylnitraat/nitriet, Androsteendion, Antazoline, Apazon, Aprindine, Aprobarbital, Arecoline, Articaïne, Atenolol, Atomoxetine, Atracurium, Atropine, Azaperon, Azapropazon, Azatadine, Baclofen, Bambuterol, Barbital, Beclamide, Bemegride, Benactyzine, Benazepril, Bendroflumethazide, Benoxaprofen, Benperidol, Benzocaïne, Benzoctamine, Benzoylecgonine, Benzquinamide, Benzydamine, Benzylpiperazine, Betamethason, Betaxolol, Biperiden, Bisoprolol, Bromantan, Bromazepam, Broomhexine, Bromisovalum, Broomperidol, Broompheniramine, Brotizolam, Bucetin, Buclizine, Bufexamac, Buflomedil, Bumetanide, Bunitrolol, Buphenine, Bupivacaïne, Bupranolol, Buprenorphine, Bupropion, Buspirone, Butabarbital, Butalbital, Butanilicaïne, Butaperazine, Cafedrine, Caffeïne, Carmazepam, Cannabis/Cannabinoids, Canrenon, Capsaicin, Captopril, Carazolol, Carbamazepine, Carbetapentane, Carbidopa, Carbimazol, Carbinoxamine, Carbromal, Carisoprodol, Carphedon, Carprofen, Carteolol, Carvedilol, Cathine, Celecoxib, Celiprolol, Ceterizine, Cetirizine, Chloralhydraat, Chloorcyclizine, Chloordiazepoxide, Chloormadinonactaat, Chloormezanon, Chloroform, Chloropyramine, Chloroquine, Chloorthiazide, Chloorphenoxamine, Chloorphentermine, Chloorpromazine, Chloorpropamide, Chloorprothixeen, Chloorthalidon, Chloorthiazide, Chloorzoxazon, Cicloprofen, Cilazapril, Cinchocaïne, Cinnarizine, Citalopram, Clemastine, Clemizole, Clenbuterol, Clobazam, Clobenzorex, Clomethiazol, Clomiphene, Clomipramine, Clomiprimine, Clonazepam, Clonidine, Clopamide, Clorazepate, Clothiapine, Clotiazepam, Cloxazolam, Clozapine, Cocaïne, Codeïne, Colchicine, Cotinine, Coumarine, Cropropamide, Crotehamide, Cyamemazine, Cyclandelaat, Cyclizine, Cyclobarbital, Cyclobenzaprine, Cyclopentamine, Cyclopentolate, Cyclothiazide, Danazol, Dantroleen, Dapson, Decamethonium, Delorazepam, Desipramine, Dextromethorphan, Dextromoramide, Dextropropoxyphene, Dextropropoxyphene, Dextrorphan, Diamorfine, Diazepam, Dibenzepin, Diclofenac, Diflunisal, Digitoxine, Dihydrocodeïne, Dihydroergotamine, Dihydromorfine, Diltiazem, Dimethylsulphoxide, Diphenhydramine, Diphenoxylaat, Diphenylpyraline, Diprophyline, Dipyrone, Disopyramide, Disulfiram, Dixyrazine, Dobutamine, Donepezil, Dopamine, Dorzolamide, Doxepin, Doxylamine, Drofenine, Droperidol, Drostanolone, Duloxetine, Methylester van Ecgonine, Eletriptan, Embutramide, Enalapril, Enalaprilaat, Ephedrine, Ergotamine, Esmolol, Estazolam, Estron, Etamiphylline, Etamivan, Ethaverine, Ethchloorvynol, Ethinamaat, Ethinylestradiol, Ethosuximide, Ethylaminobenzoaat, Ethylloflazepate, Ethylmorfine, Etidocaïne, Etilefrine, Etizolam, Etodolac, Etodroxizine, Etomidaat, Etoricoxib, Exemestane, Famprofazon, Felbamaat, Felbinac, Felodipine, Fenbutrazaat, Fencamfamine, Fenethylline, Fenetylline, Fenfluramine, Fenoprofen, Fenoterol, Fenproporex, Fentanyl, Fexofenadine, Flecaïnide, Fluanison, Fludiazepam, Flufenamicinezuur, Flunarizine, Flunitrazepam, Flunixine, Fluocortolon, Fluoxetine, Fluoxymestron, Flupenthixol, Fluphenazine, Flupirtine, Flurazepam, Flurbiprofen, Fluspirileen, Fluvoxamine, Formoterol, Furosemide, Gabapentin, Galantamine, gamma-Butyrolacton, gamma-Hydroxybutyraat, Glutethimide, Guaifenesin, Haloperidol, Harmaline, Heptaminol, Heroïne, Hexobarbital, Euregio Laboratory Services, Stadionplein 46, 6225 XW Maastricht, the Netherlands. Phone +31433620700 Histapyrrodine, Homatropine, Hydrochloorthiazide, Hydrochlorothiazide, Hydrocodon, Hydrocortison (Cortisol), Hydromorfon, Hydroxyephedrine, Hydroxyzine, Hyoscyamine, Ibuprofen, Imipramine, Indapamide, Indomethacin, Irbesartan, Isoaminile, Isoprenaline, Isoprotorenol, Isopyrine, Isothipendyl, Isradipine, Kebuzon, Ketamine, Ketazolam, Ketoprofen, Ketorolac, Ketotifen, Labetalol, Lamotrigine, Letrozol, Levallorphan, Levobunolol, Levodopa, Levorphanol, Lidocaïne, Lidoflazine, Lisinopril, Lobeline, Lofepramine, Loperamide, Loprazolam, Loratadine, Lorazepam, Lormetazepam, Losartan, Loxapine, Maprotiline, Mazindol, Methylenedioxyamphetamine, Methylenedioxy- ethylamphetamine, Methylenedioxymethamphetamine, Mebeverine, Mebhydroline, Meclizine, Meclofenaminezuur, Meclofenoxaat, Meconine, Medazepam, Medroxyprogesteron, Medrylamine, Mefenaminezuur, Mefenorex, Mefexamide, Mefruside, Meloxicam, Melperone, Memantine, Mephenesin, Mephentermine, Mephenytoïne, Meclizine, Meclofenamidezuur, Meclofenoxaat, Meconine, Medazepam, Medroxyprogesteron, Medrylamine, Mefenamidezuur, Mefenorex, Mefexamide, Mefruside, Meloxicam, Melperone, Memantine, Mephenesin, Mephentermine, Mephenytoïne, Mepindolol, Mepivacaïne, Meprobamaat, Meprobromaat, Meptazinol, Mepyramine, Mesalamine, Mesalazine, Mesoridazine, Mesterolone, Metaclazepam, Metamizole (Dipyrone), Metaraminol, Metformin, Methadon, Methapyrileen, Methaqualon, Metharbital, Methdilazine, Methocarbamol, Methohexital, Methoxyphenamine, Methsuximide, Methyldopa, Methylephedrine, Methylhexaneamine, Methylphenidate, Methylprednisolon, Methylpseudoephedrine, Methysalicylzuur, Methyprylon, Metipranolol, Metoclopramide, Metolazone, Metoprolol, Metyrapone, Mexazolam, Mexiletine, Mianserine, Midazolam, Midodrine, Mirtazepine, Modafanil, Moexipril, Mofebutazon, Molindon, Moperon, Morfine, Moxaverine, Nabumeton, Nadolol, Naftidrofuryl, Nalbuphine, Nalorphine, Naloxone, Naltrexone, Nandrolone, Naphazoline, Naproxen, Naratriptan, Nebivolol, Nefazodone, Nefopam, Nicardipine, Nicotine, Nifedipine, Nifenalol, Nifluminezuur, Nimesulide, Nimetazepam, Nimodipine, Nitrazepam, Nomifensine, Nonivamide, Nordiazepam, Norfenefrine, Norfluoxetine, Norpseudoephedrine, Nortestosteron (Nandrolon), Nortriptyline, Noscapine, Nylidrin (Buphenine), Octadecafluoronaphtaleen, Octopamine, Olanzapine, Olmesartan, Olsalazine, Opipramol, Orciprenaline, Orphenadrine, Oxabolone, Oxazepam, Oxazolam, Oxcarbazepine, Oxprenolol, Oxybuprocaïne, Oxycodon, Oxymetazoline, Oxymetholon, Oxymorphon, Oxypertine, Oxyphenbutazon, Oxyphencyclimine, Papaverine, Paracetamol, Paraldehyde, Paramethadion, Paroxetine, Penbutolol, Penfluridol, Pentazocine, Pentetrazol, Pentifylline, Pentobarbital, Pentoxifylline, Pentoxyverine, Pergolide, Periciazine, Pericyazine, Perindoprilat, Perinodopril, Perphenazine, Pethidine, Phenacetin, Phenazon, Phenazopyridine, Phencyclidine, Phendimetrazine, Phenindamine, Pheniramine, Phenmetrazine, Phenobarbital, Phenoxybenzamine, Phenprocoumon, Phentermine, Phentolamine, Phenylbutazon, Phenylephrine, Phenylpiracetam, Phenylpropanolamine, Phenyltoloxamine, Phenytoïne, Pholcodine, Pholedrine, Physostigmine, Pimozide, Pinazepam, Pindolol, Pipamperone, Pipradol, Pipradrol, Piracetam, Pirbuterol, Piroxicam, Pirprofen, Polythiazide, Prazepam, Prednisolon, Prednison, Prenylamine, Pridinol, Prilocaïne, Primidone, Probenecid, Procaïnamide, Procaïne, Procaterol, Prochloorperazine, Procyclidine, Prolintane, Promazine, Promethazine, Propafenone, Propallylonal, Propofol, Propoxyphene, Propranolol, Propylhexedrine, Propyphenazon, Proquazon, Prothipendyl, Protriptyline, Proxyphylline, Pseudoephedrine, Psilocin, Pyridostigmine, Pyrilamine, Pyrimethamine, Pyrithyldione, Pyrrobutamine, Quinalbarbital, Quinidine, Quinine, Ramifenazon (Isopyrin), Remifentanil, Reserpine, Ritodrine, Rofecoxib, Ropivacaïne, Salbutamol, Salicylamide, Salicylzuur, Scopolamine, Secobarbitone, Selegiline, Sertraline, Sibutramine, Sildenafil, Sotalol, Sparteine, Spironolacton, Stanozolol, Strychnine, Sufentanil, Sulforidazine, Sulindac, Sulpiride, Sumatriptan, Suxibuzon, Euregio Laboratory Services, Stadionplein 46, 6225 XW Maastricht, the Netherlands. Phone +31433620700 Synephrine, Tamoxifen, Temazepam, Tenoxicam, Terbutaline, Terfenadine, Testosteron, Tetracaïne, Tetrahydrogestrinon, Thebaïne, Theobromine, Theophylline, Tetrahydrogestrinon, Thiethylperazine, Thiopropazaat, Thioproperazine, Thioridazine, Tiaprofeninezuur, Tibolon, Tiletamine, Timolol, Tocaïnide, Tolfenamidezuur, Tolmetin, Torasemide, Tramadol, Tramazoline, Tranexamidezuur, Tranylcypromine, Trazodon, Triamcinolon, Triamcinolonacetonide, Triamcinolonhexacetonide, Triamterene, Triazolam, Trichloormethiazide, Trifluoperazine, Trifluoromethylphenylpiperazine, Trifluperidol, Triflupromazine, Trihexylphenidyl, Trihexyphenidyl, Trimipramine, Tripelennamine, Triprolidine, Trometamol, Tropicamide, Valdecoxib, Venlafaxine, Verapamil, Viloxazine, Warfarin, Xipamide, Xylazine, Xylometazoline, Yohimbine, Zimeldine, Zolazepam, Zolpidem, Zomepirac, Zopiclone & Zuclopenthixol. For further information regarding prices and other analyses please contact our help desk (phone +31433620700). Euregio Laboratory Services, Stadionplein 46, 6225 XW Maastricht, the Netherlands. Phone +31433620700 .
Load more

Recommended publications
  • Aldrich FT-IR Collection Edition I Library
    Aldrich FT-IR Collection Edition I Library Library Listing – 10,505 spectra This library is the original FT-IR spectral collection from Aldrich. It includes a wide variety of pure chemical compounds found in the Aldrich Handbook of Fine Chemicals. The Aldrich Collection of FT-IR Spectra Edition I library contains spectra of 10,505 pure compounds and is a subset of the Aldrich Collection of FT-IR Spectra Edition II library. All spectra were acquired by Sigma-Aldrich Co. and were processed by Thermo Fisher Scientific. Eight smaller Aldrich Material Specific Sub-Libraries are also available. Aldrich FT-IR Collection Edition I Index Compound Name Index Compound Name 3515 ((1R)-(ENDO,ANTI))-(+)-3- 928 (+)-LIMONENE OXIDE, 97%, BROMOCAMPHOR-8- SULFONIC MIXTURE OF CIS AND TRANS ACID, AMMONIUM SALT 209 (+)-LONGIFOLENE, 98+% 1708 ((1R)-ENDO)-(+)-3- 2283 (+)-MURAMIC ACID HYDRATE, BROMOCAMPHOR, 98% 98% 3516 ((1S)-(ENDO,ANTI))-(-)-3- 2966 (+)-N,N'- BROMOCAMPHOR-8- SULFONIC DIALLYLTARTARDIAMIDE, 99+% ACID, AMMONIUM SALT 2976 (+)-N-ACETYLMURAMIC ACID, 644 ((1S)-ENDO)-(-)-BORNEOL, 99% 97% 9587 (+)-11ALPHA-HYDROXY-17ALPHA- 965 (+)-NOE-LACTOL DIMER, 99+% METHYLTESTOSTERONE 5127 (+)-P-BROMOTETRAMISOLE 9590 (+)-11ALPHA- OXALATE, 99% HYDROXYPROGESTERONE, 95% 661 (+)-P-MENTH-1-EN-9-OL, 97%, 9588 (+)-17-METHYLTESTOSTERONE, MIXTURE OF ISOMERS 99% 730 (+)-PERSEITOL 8681 (+)-2'-DEOXYURIDINE, 99+% 7913 (+)-PILOCARPINE 7591 (+)-2,3-O-ISOPROPYLIDENE-2,3- HYDROCHLORIDE, 99% DIHYDROXY- 1,4- 5844 (+)-RUTIN HYDRATE, 95% BIS(DIPHENYLPHOSPHINO)BUT 9571 (+)-STIGMASTANOL
    [Show full text]
  • Arecoline Promotes Migration of A549 Lung Cancer Cells Through Activating the EGFR/Src/FAK Pathway
    toxins Article Arecoline Promotes Migration of A549 Lung Cancer Cells through Activating the EGFR/Src/FAK Pathway Chih-Hsiang Chang 1,†, Mei-Chih Chen 2,3,†, Te-Huan Chiu 1 , Yu-Hsuan Li 1, Wan-Chen Yu 1, Wan-Ling Liao 1, Muhammet Oner 1, Chang-Tze Ricky Yu 4, Chun-Chi Wu 5, Tsung-Ying Yang 6, Chieh-Lin Jerry Teng 7, Kun-Yuan Chiu 8, Kun-Chien Chen 6, Hsin-Yi Wang 9, Chia-Herng Yue 10, Chih-Ho Lai 11 , Jer-Tsong Hsieh 12 and Ho Lin 1,13,14,* 1 Department of Life Sciences, National Chung Hsing University, Taichung 40227, Taiwan; [email protected] (C.-H.C.); [email protected] (T.-H.C.); [email protected] (Y.-H.L.); [email protected] (W.-C.Y.); [email protected] (W.-L.L.); [email protected] (M.O.) 2 Medical Center for Exosomes and Mitochondria Related Diseases, China Medical University Hospital, Taichung 40447, Taiwan; [email protected] 3 Department of Nursing, Asia University, Taichung 41345, Taiwan 4 Department of Applied Chemistry, National Chi Nan University, Nantou 54561, Taiwan; [email protected] 5 Institute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan; [email protected] 6 Division of Chest Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan; [email protected] (T.-Y.Y.); [email protected] (K.-C.C.) 7 Division of Hematology/Medical Oncology, Taichung Veterans General Hospital, Taichung 40705, Taiwan; [email protected] 8 Division of Urology, Taichung Veterans General Hospital, Taichung 40705, Taiwan; [email protected] 9 Department of Nuclear Medicine, Taichung
    [Show full text]
  • AO-Klasifikácia Faktúr →Zlomeniny
    AO-klasifikácia faktúr →zlomeniny. AOP-syndróm – skr. syndroma adipositas–oligomenorrhoea–parotis. aorta – [g. aorté srdcovnica] srdcovnica. Začína sa z ľavej komory a vystupuje kraniálne aţ do výšky 2. pravého sternokostálneho kĺbu ako aorta ascendens, pokračovaním je oblúk arcus aortae, aorta descendens, aorta thoracia a aorta abdominalis. Aorta ascendens – začína sa v ľavej komore nad polmesiačikovitými chlopňami a skoro celá sa nachádza v perikarde. Je dlhá asi 4 – 5 cm, jej priemer je 22 – 30 mm. Ihneď nad chlop-ňami je následkom spätných nárazov krvi mierne vydutá do tzv. sinus aortae, výraznejšie u starších osôb. Oddiely a. obsahujúce sinus aortae sa nazývajú bulbus aortae. U starších osôb býva následkom nárazov krvi širší aj koncový úsek vzostupnej a. pred jej prechodom do oblúka, tzv. sinus maximus (quartus) aortae. Tu býva u starších osôb a. často rozširená. A. ascendens, ako aj začiatok arcus aortae majú špeciálne vasa vasorum pochádzajúce z vencovitých tepien (aa. cardiaortales). Tento úsek osobitne patogeneticky rizikový. Začiatok aorta ascendens je ešte obalený vo vagina serosa arteriarum, kt. tvorí na ventrálnom obvode a. priečnu krkvu podloţenú subseróznym tukovým väzivom (Concatova-Bacceli tuková krkva). Vnútri vagina arteriarum je aorta ascendens a začiatrok a. pulmonalis spojené tuhým väzivom (vincula aortae Rindfleischi). Výstup aorta ascendens kryje spredu začiatok a. pulmonalis, ventrálne a vpravo je auricula dextra, dorzálne je uloţený r. dexter a. pulmonalis. Kraniálne vpravo od a. je v. cava superior, vľavo kmeň a. pulmonalis. Z ventrálneho a ľavého sinus aortae sa začína a. coronaria cordis dextra et sinistra. Aorta ascendens a arcus aortae Arcus aortae – je dlhý asi 6 cm, začína sa za sternom vo výške úponu 2.
    [Show full text]
  • Did Internet-Purchased Diet Pills Cause Serotonin Syndrome?
    Did Internet-purchased diet pills cause serotonin syndrome? Phentermine also may have increased patient’s neuroleptic malignant syndrome risk s. G, age 28, presents to a tertiary® careDowden hospital Health Media with altered mental status. Six weeks ago she Mstarted taking phentermine, 37.5 mg/d, to lose weight. Her body mass indexCopyright is 24 kg/mFor2 (normal personal range), use only and she obtained the stimulant agent via the Internet. Her family reports Ms. G was very busy in the past week, staying up until 2 AM cleaning. They say she also was irritable with her 5-year-old son. Two days ago, Ms. G complained of fatigue and nausea without emesis. She went to bed early and did not awaken the next morning. Her sister found her in bed, minimally re- DIONISI sponsive to verbal stimuli, and brought her to the hospital. Patients have used phentermine as a weight-reducing IMAGES/SANDRA GETTY agent since the FDA approved this amphetamine-like © compound in 1960.1 Phentermine’s mechanism of ac- tion is thought to involve dopaminergic, noradrenergic, Kyoung Bin Im, MD and serotonergic effects.2 Stimulation of norepineph- Chief resident Internal medicine and psychiatry combined residency program rine (NE) release is its most potent effect, followed Departments of internal medicine and psychiatry by NE reuptake inhibition, stimulation of dopamine Jess G. Fiedorowicz, MD (DA) release, DA reuptake inhibition, stimulation of Associate in psychiatry serotonin (5-HT) release, and 5-HT reuptake inhibition Department of psychiatry (weak).3 Roy J. and Lucille A. Carver College of Medicine Because phentermine could in theory cause serotonin 4 University of Iowa syndrome, its use is contraindicated with monoamine Iowa City oxidase inhibitors (MAOIs) and not recommended with selective serotonin reuptake inhibitors (SSRIs).5 One case report describes an interaction between fl uox- etine and phentermine that appears consistent with se- rotonin syndrome.6 We are aware of no case reports of Current Psychiatry serotonin syndrome caused by phentermine alone.
    [Show full text]
  • The Anxiomimetic Properties of Pentylenetetrazol in the Rat
    University of Rhode Island DigitalCommons@URI Open Access Dissertations 1980 THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT Gary Terence Shearman University of Rhode Island Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss Recommended Citation Shearman, Gary Terence, "THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT" (1980). Open Access Dissertations. Paper 165. https://digitalcommons.uri.edu/oa_diss/165 This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT BY GARY TERENCE SHEARMAN A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN PHARMACEUTICAL SCIENCES (PHARMACOLOGY AND TOXICOLOGY) UNIVERSITY OF RHODE ISLAND 19 80 DOCTOR OF PHILOSOPHY DISSERT.A.TION OF GARY TERENCE SHEAffiil.AN Approved: Dissertation Cormnittee \\ Major Professor ~~-L_-_._dd__· _... _______ _ -~ar- Dean of the Graduate School UNIVERSITY OF RHODE ISLAND 1980 ABSTRACT Investigation of the biological basis of anxiety is ham­ pered by the lack of an appropriate animal model for research purposes. There are no known drugs that cause anxiety in laboratory animals. Pentylenetetrazol (PTZ) produces intense anxiety in human volunteers (Rodin, 1958; Rodin and Calhoun, 1970). Therefore, it was the major objective of this disser- tation to test the hypothesis that the discriminative stimu­ lus produced by PTZ in the rat was related to its anxiogenic action in man. It was also an objective to suggest the neuro- chemical basis for the discriminative stimulus property of PTZ through appropriate drug interactions.
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • 1-(4-Amino-Cyclohexyl)
    (19) & (11) EP 1 598 339 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 211/04 (2006.01) C07D 211/06 (2006.01) 24.06.2009 Bulletin 2009/26 C07D 235/24 (2006.01) C07D 413/04 (2006.01) C07D 235/26 (2006.01) C07D 401/04 (2006.01) (2006.01) (2006.01) (21) Application number: 05014116.7 C07D 401/06 C07D 403/04 C07D 403/06 (2006.01) A61K 31/44 (2006.01) A61K 31/48 (2006.01) A61K 31/415 (2006.01) (22) Date of filing: 18.04.2002 A61K 31/445 (2006.01) A61P 25/04 (2006.01) (54) 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ON DERIVATE UND VERWANDTE VERBINDUNGEN ALS NOCICEPTIN ANALOGE UND ORL1 LIGANDEN ZUR BEHANDLUNG VON SCHMERZ DERIVÉS DE LA 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE ET COMPOSÉS SIMILAIRES POUR L’UTILISATION COMME ANALOGUES DU NOCICEPTIN ET LIGANDES DU ORL1 POUR LE TRAITEMENT DE LA DOULEUR (84) Designated Contracting States: • Victory, Sam AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Oak Ridge, NC 27310 (US) MC NL PT SE TR • Whitehead, John Designated Extension States: Newtown, PA 18940 (US) AL LT LV MK RO SI (74) Representative: Maiwald, Walter (30) Priority: 18.04.2001 US 284666 P Maiwald Patentanwalts GmbH 18.04.2001 US 284667 P Elisenhof 18.04.2001 US 284668 P Elisenstrasse 3 18.04.2001 US 284669 P 80335 München (DE) (43) Date of publication of application: (56) References cited: 23.11.2005 Bulletin 2005/47 EP-A- 0 636 614 EP-A- 0 990 653 EP-A- 1 142 587 WO-A-00/06545 (62) Document number(s) of the earlier application(s) in WO-A-00/08013 WO-A-01/05770 accordance with Art.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST
    UFC PROHIBITED LIST Effective June 1, 2021 THE UFC PROHIBITED LIST UFC PROHIBITED LIST Effective June 1, 2021 PART 1. Except as provided otherwise in PART 2 below, the UFC Prohibited List shall incorporate the most current Prohibited List published by WADA, as well as any WADA Technical Documents establishing decision limits or reporting levels, and, unless otherwise modified by the UFC Prohibited List or the UFC Anti-Doping Policy, Prohibited Substances, Prohibited Methods, Specified or Non-Specified Substances and Specified or Non-Specified Methods shall be as identified as such on the WADA Prohibited List or WADA Technical Documents. PART 2. Notwithstanding the WADA Prohibited List and any otherwise applicable WADA Technical Documents, the following modifications shall be in full force and effect: 1. Decision Concentration Levels. Adverse Analytical Findings reported at a concentration below the following Decision Concentration Levels shall be managed by USADA as Atypical Findings. • Cannabinoids: natural or synthetic delta-9-tetrahydrocannabinol (THC) or Cannabimimetics (e.g., “Spice,” JWH-018, JWH-073, HU-210): any level • Clomiphene: 0.1 ng/mL1 • Dehydrochloromethyltestosterone (DHCMT) long-term metabolite (M3): 0.1 ng/mL • Selective Androgen Receptor Modulators (SARMs): 0.1 ng/mL2 • GW-1516 (GW-501516) metabolites: 0.1 ng/mL • Epitrenbolone (Trenbolone metabolite): 0.2 ng/mL 2. SARMs/GW-1516: Adverse Analytical Findings reported at a concentration at or above the applicable Decision Concentration Level but under 1 ng/mL shall be managed by USADA as Specified Substances. 3. Higenamine: Higenamine shall be a Prohibited Substance under the UFC Anti-Doping Policy only In-Competition (and not Out-of- Competition).
    [Show full text]
  • Programme & Abstracts
    The 57th Annual Meeting of the International Association of Forensic Toxicologists. 2nd - 6th September 2019 BIRMINGHAM, UK The ICC Birmingham Broad Street, Birmingham B1 2EA Programme & Abstracts 1 Thank You to our Sponsors PlatinUm Gold Silver Bronze 2 3 Contents Welcome message 5 Committees 6 General information 7 iCC maps 8 exhibitors list 10 Exhibition Hall 11 Social Programme 14 opening Ceremony 15 Schedule 16 Oral Programme MONDAY 2 September 19 TUESDAY 3 September 21 THURSDAY 5 September 28 FRIDAY 6 September 35 vendor Seminars 42 Posters 46 oral abstracts 82 Poster abstracts 178 4 Welcome Message It is our great pleasure to welcome you to TIAFT Gala Dinner at the ICC on Friday evening. On the accompanying pages you will see a strong the UK for the 57th Annual Meeting of scientific agenda relevant to modern toxicology and we The International Association of Forensic thank all those who submitted an abstract and the Toxicologists Scientific Committees for making the scientific programme (TIAFT) between 2nd and 6th a success. Starting with a large Young Scientists September 2019. Symposium and Dr Yoo Memorial plenary lecture by Prof Tony Moffat on Monday, there are oral session topics in It has been decades since the Annual Meeting has taken Clinical & Post-Mortem Toxicology on Tuesday, place in the country where TIAFT was founded over 50 years Human Behaviour Toxicology & Drug-Facilitated Crime on ago. The meeting is supported by LTG (London Toxicology Thursday and Toxicology in Sport, New Innovations and Group) and the UKIAFT (UK & Ireland Association of Novel Research & Employment/Occupational Toxicology Forensic Toxicologists) and we thank all our exhibitors and on Friday.
    [Show full text]